September 16, 2009 — Cancer therapies are increasingly being tailored to fit the genetic profile of the patient, but new research suggests that human epidermal growth-factor receptor (HER)2 gene ...

Changes to testing guidelines have doubled the number of patients who test positive for HER2, a protein used to diagnose breast cancer, according to a study published by Mayo Clinic researchers in the ...

Trastuzumab deruxtecan (T-DXd) has redefined the therapeutic landscape for breast cancer since its approval in 2019. Correspondingly, the relevance of HER2 testing beyond the traditional dichotomy of ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — More than one-third of U.S. adults diagnosed with metastatic HER2-negative breast cancer in 2023 ...

Biomarkers are measurable indicators that can be tested to reveal important details about a cancer. Information about these biomarkers can help guide the best treatment for you, predict your response ...

Pathological analysis of tumor microenvironmental features using deep learning to predict survival of colon carcinomas. A prospective, cross-sectional, multicentre study to evaluate the clinical ...

All patients with breast cancer who may be candidates for antibody-drug conjugate therapy should undergo HER2 testing to determine eligibility for Enhertu (fam-trastuzumab deruxtecan-nxki) — an agent ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Now, if ever there ...

Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...